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We have discovered bicyclic alkyl furano pyrimidines as a new family of selective inhibitors of varicella zoster virus (VZV) (McGuigan et al., 1999) . More recently we noted (McGuigan et al., 2000) that p-alkylphenyl analogues of type 1a-c (Figure 1 ) are exquisitely potent, with activity highly dependent on the nature of the p-phenyl substituent. Thus, as reproduced in Table 1 (McGuigan et al., 2000) the parent phenyl compound 1a shows sub-µM activity thus being ca. 10 times more potent than acyclovir in this assay. The p-pentyl compound 1c is amongst the most potent anti-VZV agents ever reported, with activity at ca. nanomolar levels (McGuigan et al., 2000) . We have also noted (McGuigan et al., 2001 ) that the p-chloro and p-bromophenyl compounds (2b-c) have similar activities to the phenyl and toluoyl systems (1a-b), with the chloro compound being slightly more active. In this manuscript we report studies to extend this work to the fluoro analogue and to pursue otho-and meta-substituted isomers of a variety of halogen substitutents.
Materials and methods

Chemistry
General methods: see McGuigan et al., 1999 McGuigan et al., , 2000 Standard procedure for the preparation of 2,3-dihydrofuro[2,3-d] pyrimidin-2-one nucleosides 5-iodo-2′-deoxyuridine (1.0 mol. equiv.) was dissolved in dry DMF (~10 ml) and stirred at room temperature under N 2 . Dry diisopropylethylamine (2.0 mol. equiv.), the appropriate alkyne (3-3.5 mol. equiv.), tetrakis (triphenylphosphine) palladium (0) (0.1 mol. equiv.) and copper (I) iodide (0.2 mol. equiv.) were added and the reaction mixture was stirred at room temperature overnight under N 2 . Triethylamine (10 ml), methanol (10 ml) and copper (I) iodide 0.2 equiv were added and the mixture was heated under reflux for 4-5 h. The solvent was removed under reduced pressure and the remaining residue was re-dissolved in DCM:MeOH (1:1,~20 ml). An excess of amberlite IRA-400 (HCO 3 form) was added and the suspension was stirred for 30 min. The reaction mixture was filtered and washed with methanol; the solvent was removed under reduced pressure to leave the crude residue. This was purified by column chromatography and /or recrystallization from suitable solvents. Analytical data on final products were within accepted limits; these data are on file with the Editorial Office.
Halophenyl furanopyrimidines as potent and selective anti-VZV agents
The procedure was carried out using 4-fluorophenylacetylene (1.25 g, 6.76 mmol), which gave 3-(2-deoxy- 13 C-NMR (d 6 -DMSO) 41.8 (C-2′), 60.9 (C-5′), 69.8 (C-3′), 87.9, 88.5 (C-1′, C-4′), 100.2 (C-5), 107.5 (C-4a), 116.5 (C-Hb), 127.2 (ipso-C), 127.9 (C-H a ), 136.4 (C-4), 153.2 (para-C), 154.1 (C-6), 160.2 (C-2), 171.4 (C-7a).
3-(2-deoxy-β-D-ribofuranosyl)-6-(4-chlorophenyl)-2,3-dihydrofuro-[2,3-d]pyrimidin-2-one (2b)
The procedure was carried out using 4-n-chlorophenylacetylene (0.92 g, 6.76 mmol), which gave 3-(2-deoxy-β-
2.41 and 2.13 (2H, m, 2-H′a and 2-H′b).
13 CNMR (d 6 -DMSO) 41.6 (C-2′), 60.9 (c-5′), 69.8 (C-3′), 88.0, 88.5, (C-1′, C-4′), 100.8 (C-5), 107.0 (C-4a), 126.6 (C-Hb), 127.6 (ipso-C), 129.6 (C-Ha), 134.2 (C-4), 152.8 (para-C), 154.1 (C-6), 161.2 (C-2), 171.8 (C-7a 
3-(2-deoxy-β-D-ribofuranosyl)-6-(4-bromophenyl)-2,3-dihydrofuro-[2,3-d] pyrimidin-2-one (2c)
The procedure was carried out using 4-bromophenylacetylene (1.22 g, 6.76 mmol), which gave 3-( 13 CNMR (d 6 -DMSO) 41.6 (C-2′), 60.9 (c-5′), 69.8 (C-3′), 88.1, 88.5, (C-1′, C-4′), 100.9 (C-5), 107.0 (C-4a), 122.9 (CHb), 126.8 (ipso-C), 127.9 (C-Ha), 139.0 (C-4), 152.8 (para-C), 154.1 (C-6), 160.9 (C-2), 171.3 (C-7a 
3-(2-deoxy-β-D-ribofuranosyl)-6-(3-fluorophenyl)-2,3-dihydrofuro-[2,3-d]pyrimidin-2-one (3a)
1-Fluoro-3-iodobenzene (0.24 ml, 0.45g, 2.02 mmol, 1 eq) was dissolved in DMF (15 ml) and the solution degassed with Argon for 30 min. Following this, 5-ethynyl-2′-deoxyuridine (EDU) (0.61 g, 2.42 mmol, 1.2 eq) was added together with dichlorobis diphenylphosphine palladium (II) [PdCl 2 (PPh 3 ) 2 ] (0.14 g, 0.1 eq), triphenylphosphine (PPh 3 ) (0.05 eq, 0.03 g) and DIPEA (2 eq, 0.52 g, 0.70 ml). The mixture was allowed to react for 10 min at RT under Argon before adding Cul (0.2 eq, 4.04x10 -4 mol, 0.08 g) and stirring at RT for 18 h. The solvents were removed under vacuum and the residue dissolved in methanol (20 ml). Triethylamine (5 ml) and Cul (0.08 g, 0.2 eq) were added and the mixture refluxed for 5 h and the reaction mixture stirred for 12 h at RT. The solvent was removed under reduced pressure and flash column chromatography (silica gel; 5% MeOH/95% EtOAc) yielded the cyclized product as a white crystalline solid (49%). 
3-(2-deoxy-β-D-ribofuranosyl)-6-(3-chlorophenyl)-2,3-dihydrofuro-[2,3-d]pyrimidin-2-one (3b)
1-Chloro-3-iodobenzene (0.23 ml, 1 eq, 1.85 mmol) was dissolved in DMF (20 ml) and the solution degassed with Argon for 15 min. Following this, PdCl 2 (PPh 3 ) 2 (0.13 g, 0.1 eq, 0.185 mmol), DIPEA (2 eq, 3.7 mmol, 0.48 g 0.65 ml), Cul (0.2 eq, 0.07 g, 0.37 mmol) was added and the mixture was stirred for 2 min under argon. A yellow precipitate was observed. EDU (5-ethynyl-2′-deoxyuridine) was added next (1.5 eq, 0.6 g 2.78 mmol) and stirring continued at room temp. for 12 h. To the flask were added methanol (20 ml), triethylamine (5 ml), and Cul (0.2 eq, 0.07 g) and the mixture refluxed for 5 h.
All solvents were removed under vacuum to leave a brown solid. This was suspended in methanol and heated to reflux for 2 h. Residual Cul was filtered off to leave a homogeneous solution. On cooling, a pale yellow solid precipitated out. This was filtered off and found to be the cyclised product 3b (55% 
3-(2-deoxy-β-D-ribofuranosyl)-6-(3-bromophenyl)-2,3-dihydrofuro-[2,3-d]pyrimidin-2-one (3c)
This was prepared by an identical method to 3a, above, except using 1-iodo-3-bromobenzene. Yield 29%. 
3-(2-deoxy-β-D-ribofuranosyl)-6-(2-fluorophenyl)-2,3-dihydrofuro-[2,3-d]pyrimidin-2-one (4a)
Prepared from 1 ethynyl-2-fluorobenzene using the standard method. The product was recovered by flash chromatography (silica gel: 10% MeOH/90% EtOAc). Yield= 62%. 1 H NMR (d 6 DMSO) 8.9 (1H, s, H4), 7.7 (2H, m, Ha.), 7.5 (2H, m, Hb), 7.1 (1H, d, H5 
3-(2-deoxy-β-D-ribofuranosyl)-6-(2-chlorophenyl)-2,3-dihydrofuro-[2,3-d]pyrimidin-2-one (4b)
Prepared by the standard method. 
3-(2-deoxy-β-D-ribofuranosyl)-6-(2-bromophenyl)-2,3-dihydrofuro-[2,3-d]pyrimidin-2-one (4c)
1-Bromo-2-iodobenzene (0.18 ml, 1.39 mmol, 0.39 g, 1 eq) was dissolved in acetonitrile (20 ml) and the solution degassed with Argon for 30 min. To this was added (under Argon, constant stirring) PdCl 2 (PPh 3 ) 2 (0.1 eq, 0.10 g), DIPEA (2 eq, 2.78 mmol, 0.36 g), EDU (0.70 g, 2 eq, 2.78 mmol) and Cul (0.2 eq, 0.05 g) and the mixture stirred at reflux for 1 h. To the reaction mixture was added methanol (20 ml). Triethylamine (5 ml) and Cul (0.05 g, 0.2 eq) and the mixture refluxed for a further 2 h. Heating was stopped and all volatiles removed under reduced pressure. The residue was treated with methanol (30 ml); a fine brown precipitate resulted. This was filtered off, suspended in fresh methanol (30 ml), heated to reflux and then filtered. The filtrate, once cooled yielded a white precipitate later confirmed as the cyclized product (Yield=16%).
1 H NMR (d 6 DMSO) 8.91 (1H, s, H4), 7.48-7.99 (4H, m, H a , H b ), 7.21 (1H, s, H5), 6.24 (1H, t, H1′), 5.37 (1H, d, 3′OH), 5.14 (1H, t, 5′OH), 4.37 (1H, m, H3′), 4.01 (1H, m, H4'), 3.74 (2H, m, H5′), 2.14 and 2.51 (2H, m, H2′a, H2′b). MS (ES + ): m/e=431.2 (MNa + , 100%).
Results
The initial target was the p-fluorophenyl compound 2a which was prepared from 5-iodo-2′-deoxy uridine (IDU) following exactly the procedures we have previously reported (McGuigan et al., 2000) . Thus, IDU was allowed to react with p-fluorophenyl acetylene under Pd and Cu catalysis to give the intermediate 5-alkyaryl nucleoside which was not isolated but allowed to react in situ with CuI to generate 2a in one pot. The chloro (2b) and bromo (2c) analogues were prepared by an identical method (Scheme). In the case of the meta isomers 3a-c an alternative route involving the reaction of 5-ethynyl-2′-deoxyuridine (Robins and Barr, 1983) with the appropriate halo iodobenzene gave preferable yields. For the ortho compounds, the fluoro (4a) and chloro (4b) were prepared from IDU by the standard method whilst the bromo (4c) was prepared via EDU. All compounds were fully characterized by a range of analytical and spectroscopic methods. This included high field C-13 NMR, for which data are included in Table 2 .
Discussion
Compounds were evaluated for their ability to inhibit the replication of VZV OKA and YS in cell culture, with data being included in Table 1 . Most striking of all, and in contrast to all prior aryl compounds we have prepared in this programme (McGuigan et al., 2001) , the p-fluorophenyl analogue 2a was found to be inactive against VZV. Thus, 2a is >100 fold less active than the phenyl parent 1a. This is surprising based on the similarity of H and F, and the earlier observation that the Cl and Br analogues (2b, 2c) retain or exceed the potency of the phenyl parent. Clearly, the fluorine substituent is more electronegative than either the Cl, Br or the H of the parent, and this may be a factor in the inactivity of 2a. However, ClogP calculations reveal that F has little impact on the overall lipophilicity of the compound, a factor we have previously found to be predictive of anti-VZV potency in this series (Table 1) (McGuigan et al., 2001) .
Comparing the regioisomers of 2a, although the meta compound 3a does display some activity, being 10-20 times less active than the parent 1a. The ortho fluoro 4a is most potent of all; at 30-40 nM it is >1000 fold more potent than 2a. Thus, comparing 2a, 3a and 4a reveals a marked dependence on the halogen location for anti-VZV activity, with EC 50 values of >50, 1.3 and 0.04 µM vs VZV OKA respectively. Whilst the o-F displays a slight potency advantage over the parent, and the m-F a slight potency disadvantage, the P-F is inactive. The mechanistic origins of this observation are currently unknown but may relate to the interaction of 2a with VZV thymidine kinase (Balzarini et al, 2002) .
The effect of other halogen substitution in the aryl moiety is rather different. Thus, for both chloro and bromo substitution, the order of decreasing potency is ortho >para >meta. For any given position the chloro and bromo substitutents are roughly equi-potent. Again, as with o-fluoro, the o-substitution by Cl or Br leads to an enhanced potency by comparison to the parent phenyl 1a. The most potent compounds to emerge are 4b-c, the ortho Cl-and Br-; these are ca 10-fold more potent than the phenyl parent 1a.
Indeed, 4b-4c are ca 5-fold more potent than would have been predicted from their ClogP alone, which would have suggested a potency similar to that of 1b.
Finally, to note that none of the present compounds display any activity vs. TK-deficient VZV, as we have noted previously, and none of the compounds were significantly cytotoxic at effective concentrations.
In conclusion, we report the synthesis and anti VZV activity of ortho-, meta-and para-fluoro-, chloro-, and bromo-substituted phenyl furanopyrimidines. Ortho substitution may have some advantages in drug optimization. 
